Suppr超能文献

魁北克大麻登记处不良事件报告的描述性分析。

A Descriptive Analysis of Adverse Event Reports from the Quebec Cannabis Registry.

机构信息

Medical Cannabis Program in Oncology, McGill University Health Center, Montréal, QC, Canada.

Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.

出版信息

Drug Saf. 2024 Feb;47(2):161-171. doi: 10.1007/s40264-023-01379-0. Epub 2023 Nov 23.

Abstract

INTRODUCTION

Published data on the safety of natural medical cannabis (MC) when used in the real-world clinical practice setting are lacking. This study aimed to describe adverse events (AEs) reported across three years following MC initiation.

METHODS

The Quebec Cannabis Registry (QCR) was a prospective registry of adults enrolled through participating physicians when they initiated MC between May 2015 and October 2018. Follow-up ended at MC discontinuation, loss to follow-up, three years, or end of data collection (May 2019). Data were collected at baseline and at follow-up visits every three months for the first two years, then once in the third year. Physicians filled adverse event (AE) reports, which were coded using MedDRA preferred terms (PTs), and descriptive analyses were conducted.

RESULTS

A total of 2991 patients were enrolled (mean age 50.9 years, 50.2% females). During follow-up, 108 patients (3.6%) experienced moderate or severe AEs, yielding 111 AE reports (three patients had two reports) and 214 AEs (average 1.9 AEs per report). Mild AEs were recorded as a reason for MC discontinuation for nine patients, but no AE reports were available. The most common PTs for ingested MC (62 reports) were dizziness (12.9%), nausea (11.3%), somnolence (9.7%), and vomiting (8.1%), and for inhaled MC (23 reports), headache (13.0%) was the most common. The most frequent PTs associated with tetrahydrocannabinol (THC)-dominant MC (25 reports) were dizziness and somnolence (12.0% each); for cannabidiol (CBD)-dominant MC (20 reports), vomiting (20.0%) was most common; and dizziness (17.2%), nausea (13.8%), somnolence (10.3%), and headache (8.6%) were the most frequent for balanced MC (58 reports).

CONCLUSION

No new safety concerns were identified relative to the published literature, although notable differences in AE profile between modes of administration and cannabinoid content ratios should be considered by health professionals. Further work identifying and managing risk factors for AEs is warranted to maintain a favorable benefit-risk balance for MC.

摘要

简介

缺乏关于在真实临床环境中使用天然医用大麻(MC)的安全性的已发表数据。本研究旨在描述 MC 启动后三年内报告的不良事件(AE)。

方法

魁北克大麻登记处(QCR)是一项前瞻性登记处,纳入了 2015 年 5 月至 2018 年 10 月期间参与医生招募的成年人。随访在 MC 停药、失访、三年或数据收集结束(2019 年 5 月)时结束。基线时收集数据,并在接下来的两年中每三个月随访一次,然后在第三年随访一次。医生填写不良事件(AE)报告,使用 MedDRA 首选术语(PT)进行编码,并进行描述性分析。

结果

共纳入 2991 名患者(平均年龄 50.9 岁,50.2%为女性)。在随访期间,108 名患者(3.6%)出现中度或重度 AE,共报告 111 例 AE(3 名患者报告 2 例)和 214 例 AE(平均每例报告 1.9 例)。9 名患者因轻度 AE 而停止使用 MC,但没有 AE 报告。摄入 MC 最常见的 PT(62 例)为头晕(12.9%)、恶心(11.3%)、嗜睡(9.7%)和呕吐(8.1%),吸入 MC 最常见的 PT(23 例)为头痛(13.0%)。与四氢大麻酚(THC)为主的 MC(25 例)相关的最常见 PT 为头晕和嗜睡(各占 12.0%);与大麻二酚(CBD)为主的 MC(20 例)相关的最常见 PT 为呕吐(20.0%);与平衡 MC(58 例)相关的最常见 PT 为头晕(17.2%)、恶心(13.8%)、嗜睡(10.3%)和头痛(8.6%)。

结论

与已发表文献相比,没有发现新的安全性问题,但应考虑不同给药方式和大麻素含量比之间 AE 谱的显著差异。需要进一步开展工作,以确定和管理 AE 的风险因素,以维持 MC 的有利风险效益平衡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验